|ASMB -- USA Stock|| |
USD 46.96 0.83 1.80%
Vice President - Research & Development, Chief Medical Officer
Dr. Uri Lopatin, M.D. is Vice President Research Development, Chief Medical Officer of ASSEMBLY BIOSCIENCES, Inc. At Assembly Pharmaceuticals, he was Chief Medical Officer and Vice President Research and Development, a position he held since October, 2012. Prior to that, he was a Senior Director for Clinical and Translational ResearchLiver Disease at Gilead Sciences from October, 2010 to September, 2012, a Translational Medical Leader at Roche from May, 2008 to September, 2010. He has designed and coordinated preclinical and clinical collaborations, as well as phase I through IV clinical studies of multiple new molecular entities. Dr. Lopatin has published extensively, especially on hepatitis B and immunology and is an author of multiple patents in the field of treatment and diagnosis for viral hepatitis. Dr. Lopatin received his infectious disease Board certification following fellowship training in ID at the NIH, and internal medicine board certification following completion of residency at NYU. He received his MD in 2000 from University of Medicine and DentistryNew Jersey Medical School.
Age: 42 President Since 2014 Ph.D
Lopatin received his infectious disease Board certification following fellowship training in ID at the NIH, and internal medicine board certification following completion of residency at NYU. He received his MD in 2000 from University of Medicine and DentistryNew Jersey Medical School, where he was the recipient of the Stanley S Bergen medal of excellence. He holds a BA in biology from Cornell University, where he graduated cum laude with distinction in all subjects.
Uri Lopatin Latest Insider Activity
The company has return on total asset (ROA)
of (24.41) %
which means that it has lost $24.41 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE)
of (44.36) %
meaning that it created substantial loss on money invested by shareholders.
Assembly Biosciences, Inc. operates as a clinical stage biotechnology company. Assembly Biosciences, Inc. was founded in 2005 and is headquartered in Carmel, Indiana. Assembly Biosciences operates under Biotechnology classification in USA and traded on Nasdaq Capital Markets. It employs 79 people.Assembly Biosciences (ASMB) is traded on Nasdaq Capital Markets in USA. It is located in NEW YORK, U.S.A and employs 79 people. Assembly Biosciences is listed under Pharmaceutical Products category by Fama And French industry classification.
Assembly Biosciences Leadership Team
|Uri Lopatin, President, Ph.D|
|Helen Kim, Director, MBA|
|Myron Holubiak, Director|
|Lee Arnold, Executive, Ph.D|
|Anthony Altig, Director|
|Richard Colonno, Executive|
|Graham Cooper, COO, MBA|
|William Ringo, Chairman, MBA|
|Susan Mahony, Director|
|Richard DiMarchi, Director, Ph.D|
|Miguel Barbosa, Executive, Ph.D|
|Thomas Rollins, Executive|
|Mark Auerbach, Director|
|Derek Small, CEO|
|Alan Lewis, Director, Ph.D|
|David Barrett, COO|
Stock Performance Indicators
Most of Macroaxis users are presently bullish on Assembly Biosciences. What is your sentiment towards investing in Assembly Biosciences? Are you bullish or bearish?
and pair trading evaluation for Assembly Biosciences and NantKwest
. Pair trading can be used as a hedging technique within a particular sector or industry or even over random equities to generate better risk-adjusted return